Collection
Liquid Biopsy in Breast Cancer
- Submission status
- Open
- Open for submission from
- 01 July 2022
- Submission deadline
- Ongoing
Liquid biopsy, the analysis of circulating markers in the blood of cancer patients, is a fast-moving research space. There is tremendous excitement for the clinical adoption of liquid biopsy given the potential for it to revolutionise cancer screening, including breast cancer screening.
In this collection, we welcome studies investigating the diverse range of circulating markers - such as circulating DNA (ctDNA), circulating tumour cells and exosomes - for breast cancer diagnosis and treatment.
Articles (10 in this collection)
-
-
Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(−) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice
Authors (first, second and last of 12)
- Manali A. Bhave
- Julia C. F. Quintanilha
- Kevin Kalinsky
- Content type: Research
- Open Access
- Published: 14 June 2024
-
Circulating tumour DNA dynamics during alternating chemotherapy and hormonal therapy in metastatic breast cancer: the ALERT study
Authors (first, second and last of 9)
- Rebecca C. Allsopp
- Qi Guo
- Jacqueline A. Shaw
- Content type: Research
- Open Access
- Published: 06 April 2024
- Pages: 377 - 385
-
Variant allele frequency in circulating tumor DNA correlated with tumor disease burden and predicted outcomes in patients with advanced breast cancer
Authors (first, second and last of 8)
- Jianxin Zhong
- Hanfang Jiang
- Huiping Li
- Content type: Original Laboratory Investigation
- Open Access
- Published: 06 January 2024
- Pages: 617 - 629
-
Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer
Authors (first, second and last of 13)
- Tom Wei-Wu Chen
- Wen Hsiao
- Yen-Shen Lu
- Content type: Clinical trial
- Open Access
- Published: 21 June 2023
- Pages: 377 - 385
-
Heterogeneous circulating tumor cells correlate with responses to neoadjuvant chemotherapy and prognosis in patients with locally advanced breast cancer
Authors (first, second and last of 9)
- Ge Ma
- Jingyi Wang
- Shui Wang
- Content type: Preclinical study
- Published: 13 June 2023
- Pages: 27 - 41
-
Efficacy relevance of PD-L1 expression on circulating tumor cells in metastatic breast cancer patients treated with anti-PD-1 immunotherapy
Authors (first, second and last of 10)
- Ying Zhou
- Jinmei Zhou
- Tao Wang
- Content type: Original Laboratory Investigation
- Published: 25 May 2023
- Pages: 281 - 291
-
Implications for surveillance for breast cancer patients based on the internally and externally validated BRENDA-metastatic recurrence score
Authors (first, second and last of 8)
- Florian Ebner
- Jessica Salmen
- Manfred Wischnewsky
- Content type: Epidemiology
- Open Access
- Published: 14 March 2023
- Pages: 173 - 184
-
Blood plasma derived extracellular vesicles (BEVs): particle purification liquid chromatography (PPLC) and proteomic analysis reveals BEVs as a potential minimally invasive tool for predicting response to breast cancer treatment
Authors (first, second and last of 9)
- Folnetti A. Alvarez
- Hussein Kaddour
- Chioma M. Okeoma
- Content type: Brief Communication
- Published: 17 September 2022
- Pages: 423 - 437
-
Comparison of microfluidic platforms for the enrichment of circulating tumor cells in breast cancer patients
Authors (first, second and last of 9)
- Constantin Sajdik
- Eva Schuster
- Eva Obermayr
- Content type: Preclinical study
- Open Access
- Published: 08 September 2022
- Pages: 75 - 85